107 related articles for article (PubMed ID: 14641143)
1. Nonmyeloablative stem cell transplantation with fludarabine and cyclophosphamide for patients with hematologic malignancies.
Nakajima H; Oki M; Kishi K; Ueyama J; Miyakoshi S; Hatsumi N; Sakura T; Miyawaki S; Yokota A; Fujisawa S; Mori S; Tanaka Y; Sakamaki H;
Clin Lab Haematol; 2003 Dec; 25(6):383-91. PubMed ID: 14641143
[TBL] [Abstract][Full Text] [Related]
2. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
Ogawa H; Ikegame K; Yoshihara S; Kawakami M; Fujioka T; Masuda T; Taniguchi Y; Hasei H; Kaida K; Inoue T; Kim EH; Kawase I
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1073-84. PubMed ID: 17084371
[TBL] [Abstract][Full Text] [Related]
3. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies.
Spitzer TR; McAfee S; Sackstein R; Colby C; Toh HC; Multani P; Saidman S; Weyouth DW; Preffer F; Poliquin C; Foley A; Cox B; Andrews D; Sachs DH; Sykes M
Biol Blood Marrow Transplant; 2000; 6(3A):309-20. PubMed ID: 10905768
[TBL] [Abstract][Full Text] [Related]
4. Mixed chimerism and graft failure following conditioning with the fludarabine and cyclophosphamide nonablative regimen; conversion to full donor chimerism.
Jillella AP; Shafer D; Klumpp TR; Emmons RV; Mangan KF
Am J Hematol; 2007 Jun; 82(6):419-26. PubMed ID: 17211845
[TBL] [Abstract][Full Text] [Related]
5. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies.
Corradini P; Tarella C; Olivieri A; Gianni AM; Voena C; Zallio F; Ladetto M; Falda M; Lucesole M; Dodero A; Ciceri F; Benedetti F; Rambaldi A; Sajeva MR; Tresoldi M; Pileri A; Bordignon C; Bregni M
Blood; 2002 Jan; 99(1):75-82. PubMed ID: 11756155
[TBL] [Abstract][Full Text] [Related]
6. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease.
Brunstein CG; Barker JN; Weisdorf DJ; DeFor TE; Miller JS; Blazar BR; McGlave PB; Wagner JE
Blood; 2007 Oct; 110(8):3064-70. PubMed ID: 17569820
[TBL] [Abstract][Full Text] [Related]
7. A 5-day cytoreductive chemotherapy followed by haplo-identical hsct (FA5-BUCY) as a tumor-ablative regimen improved the survival of patients with advanced hematological malignancies.
Yang T; Lin Q; Ren J; Chen P; Yuan X; Luo X; Liu T; Zheng J; Zheng Z; Zheng X; Chen X; Zhang L; Zheng H; Chen Z; Hua X; Le S; Li J; Chen Z; Hu J
Oncotarget; 2016 Nov; 7(48):78773-78786. PubMed ID: 27705929
[TBL] [Abstract][Full Text] [Related]
8. Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.
Devine SM; Sanborn R; Jessop E; Stock W; Huml M; Peace D; Wickrema A; Yassine M; Amin K; Thomason D; Chen YH; Devine H; Maningo M; van Besien K
Bone Marrow Transplant; 2001 Sep; 28(6):557-62. PubMed ID: 11607768
[TBL] [Abstract][Full Text] [Related]
9. Reliable engraftment, low toxicity, and durable remissions following allogeneic blood stem cell transplantation with minimal conditioning.
Kobbe G; Schneider P; Aivado M; Zohren F; Schubert D; Fenk R; Neumann F; Kronenwett R; Pape H; Rong A; Royer-Pokora B; Hildebrandt B; Germing U; Gattermann N; Heyll A; Haas R
Exp Hematol; 2002 Nov; 30(11):1346-53. PubMed ID: 12423689
[TBL] [Abstract][Full Text] [Related]
10. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
[TBL] [Abstract][Full Text] [Related]
11. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
Shore T; Harpel J; Schuster MW; Roboz GJ; Leonard JP; Coleman M; Feldman EJ; Silver RT
Biol Blood Marrow Transplant; 2006 Aug; 12(8):868-75. PubMed ID: 16864057
[TBL] [Abstract][Full Text] [Related]
12. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders.
Pérez-Simón JA; Kottaridis PD; Martino R; Craddock C; Caballero D; Chopra R; García-Conde J; Milligan DW; Schey S; Urbano-Ispizua A; Parker A; Leon A; Yong K; Sureda A; Hunter A; Sierra J; Goldstone AH; Linch DC; San Miguel JF; Mackinnon S;
Blood; 2002 Nov; 100(9):3121-7. PubMed ID: 12384408
[TBL] [Abstract][Full Text] [Related]
13. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
14. Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia.
Stein AS; Palmer JM; O'Donnell MR; Kogut NM; Spielberger RT; Slovak ML; Tsai NC; Senitzer D; Snyder DS; Thomas SH; Forman SJ
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1407-14. PubMed ID: 19822300
[TBL] [Abstract][Full Text] [Related]
15. Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.
Alousi AM; Brammer JE; Saliba RM; Andersson B; Popat U; Hosing C; Jones R; Shpall EJ; Khouri I; Qazilbash M; Nieto Y; Shah N; Ahmed S; Oran B; Al Atrash G; Ciurea S; Kebriaei P; Chen J; Rondon G; Champlin RE
Biol Blood Marrow Transplant; 2015 May; 21(5):906-12. PubMed ID: 25667989
[TBL] [Abstract][Full Text] [Related]
16. Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia.
Schlenk RF; Hartmann F; Hensel M; Jung W; Weber-Nordt R; Gabler A; Haas R; Ho AD; Trümper L; Döhner H
Leukemia; 2002 Apr; 16(4):581-6. PubMed ID: 11960336
[TBL] [Abstract][Full Text] [Related]
17. Nonmyeloablative stem cell transplantation with CD8-depleted or CD34-selected peripheral blood stem cells.
Baron F; Baudoux E; Frère P; Tourqui S; Schaaf-Lafontaine N; Greimers R; Herens C; Fillet G; Beguin Y
J Hematother Stem Cell Res; 2002 Apr; 11(2):301-14. PubMed ID: 11983101
[TBL] [Abstract][Full Text] [Related]
18. Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies.
van Besien K; Devine S; Wickrema A; Jessop E; Amin K; Yassine M; Maynard V; Stock W; Peace D; Ravandi F; Chen YH; Cheung T; Vijayakumar S; Hoffman R; Sosman J
Bone Marrow Transplant; 2003 Jul; 32(1):9-13. PubMed ID: 12815472
[TBL] [Abstract][Full Text] [Related]
19. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
[TBL] [Abstract][Full Text] [Related]
20. Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies.
Alessandrino EP; Bernasconi P; Colombo AA; Caldera D; Malcovati L; Troletti D; Vanelli L; Varettoni M; Montanari F; Lazzarino M
Bone Marrow Transplant; 2004 Dec; 34(12):1039-45. PubMed ID: 15516936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
